179 related articles for article (PubMed ID: 29481917)
1. Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation.
Losina E; Usiskin IM; Smith SR; Sullivan JK; Smith KC; Hunter DJ; Messier SP; Paltiel AD; Katz JN
Osteoarthritis Cartilage; 2018 May; 26(5):641-650. PubMed ID: 29481917
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
Katz JN; Smith SR; Collins JE; Solomon DH; Jordan JM; Hunter DJ; Suter LG; Yelin E; Paltiel AD; Losina E
Osteoarthritis Cartilage; 2016 Mar; 24(3):409-18. PubMed ID: 26525846
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.
Karasawa Y; Kamae I; Nozawa K; Zeniya S; Murata T; Soen S; Sakamoto C
PLoS One; 2021; 16(7):e0253547. PubMed ID: 34228745
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
5. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.
Losina E; Michl G; Collins JE; Hunter DJ; Jordan JM; Yelin E; Paltiel AD; Katz JN
Osteoarthritis Cartilage; 2016 May; 24(5):776-85. PubMed ID: 26746146
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan.
Yen ZS; Lai MS; Wang CT; Chen LS; Chen SC; Chen WJ; Hou SM
J Rheumatol; 2004 Sep; 31(9):1797-803. PubMed ID: 15338503
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of duloxetine for knee OA subjects: the role of pain severity.
Sullivan JK; Huizinga J; Edwards RR; Hunter DJ; Neogi T; Yelin E; Katz JN; Losina E
Osteoarthritis Cartilage; 2021 Jan; 29(1):28-38. PubMed ID: 33171315
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J
Semergen; 2016; 42(4):235-43. PubMed ID: 26006311
[TBL] [Abstract][Full Text] [Related]
9. An economic model of long-term use of celecoxib in patients with osteoarthritis.
Loyd M; Rublee D; Jacobs P
BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis.
Smith SR; Katz JN; Collins JE; Solomon DH; Jordan JM; Suter LG; Yelin EH; David Paltiel A; Losina E
Arthritis Care Res (Hoboken); 2017 Feb; 69(2):234-242. PubMed ID: 27111538
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
Brereton N; Pennington B; Ekelund M; Akehurst R
J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic regimens for knee osteoarthritis prevention: can they be cost-effective?
Losina E; Burbine SA; Suter LG; Hunter DJ; Solomon DH; Daigle ME; Dervan EE; Jordan JM; Katz JN
Osteoarthritis Cartilage; 2014 Mar; 22(3):415-30. PubMed ID: 24487044
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
14. Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib.
Holt RJ; Fort JG; Grahn AY; Kent JD; Bello AE
Phys Sportsmed; 2015 Jul; 43(3):200-12. PubMed ID: 26313454
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis and economic burden of knee osteoarthritis treatment: the analysis from the real clinical practice.
Turajane T; Chaweevanakorn U; Sungkhun P; Larbphiboonpong V; Wongbunnak R
J Med Assoc Thai; 2012 Oct; 95 Suppl 10():S98-104. PubMed ID: 23451446
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?
Losina E; Daigle ME; Suter LG; Hunter DJ; Solomon DH; Walensky RP; Jordan JM; Burbine SA; Paltiel AD; Katz JN
Osteoarthritis Cartilage; 2013 May; 21(5):655-67. PubMed ID: 23380251
[TBL] [Abstract][Full Text] [Related]
18. Does Screening for Depressive Symptoms Help Optimize Duloxetine Use in Knee Osteoarthritis Patients With Moderate Pain? A Cost-Effectiveness Analysis.
Lenhard NK; Sullivan JK; Ross EL; Song S; Edwards RR; Hunter DJ; Neogi T; Katz JN; Losina E
Arthritis Care Res (Hoboken); 2022 May; 74(5):776-789. PubMed ID: 33253496
[TBL] [Abstract][Full Text] [Related]
19. Efficiency of naproxen/esomeprazole in association for osteoarthrosis treatment in Spain.
Capel M; Tornero J; Zamorano JL; Oyagüez I; Casado MÁ; Sánchez-Covisa J; Lanas A
Reumatol Clin; 2014; 10(4):210-7. PubMed ID: 24380809
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis.
Losina E; Smith KC; Paltiel AD; Collins JE; Suter LG; Hunter DJ; Katz JN; Messier SP
Arthritis Care Res (Hoboken); 2019 Jul; 71(7):855-864. PubMed ID: 30055077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
